Tag: Weill Cornell
-
Researchers to study the economics of substance use disorder treatments with $4 million NIDA grant
Five-Year, $4 Million NIDA Grant Launches Health Economics Study A collaborative research effort led by Weill Cornell Medicine and the University of Miami’s Miller School of Medicine has been awarded a five-year, $4 million grant from the National Institute on Drug Abuse (NIDA). The study aims to advance understanding of the economics surrounding treatments for…
-
Babak J. Mehrara, MD, Named President of The Plastic Surgery Foundation to Advance Research and Global Collaboration
New Leadership to Accelerate Research and Global Collaboration in Plastic Surgery Babak J. Mehrara, MD, FACS, has been appointed president of The Plastic Surgery Foundation (The PSF), a pivotal organization that supports research and international activities of the American Society of Plastic Surgeons (ASPS). The announcement comes as The PSF reinforces its commitment to advancing…
-
EZH2 Inhibition Blocks TNBC Metastasis and Restores Chromosomal Stability
New findings link EZH2 to chromosomal chaos and metastasis in TNBC Triple-negative breast cancer (TNBC) remains one of the most challenging cancer types to treat due to its aggressive nature and lack of targeted hormones. A groundbreaking preclinical study from Weill Cornell Medicine, published in Cancer Discovery, identifies a surprising driver of TNBC metastasis and…
-
Blocking TNBC Metastasis by Restoring Chromosomal Stability via EZH2 Inhibition
New findings link EZH2 to TNBC metastasis and chromosomal instability Triple negative breast cancer (TNBC) remains one of the most challenging cancer types to treat, largely due to its propensity to spread to distant organs. A new preclinical study led by Weill Cornell Medicine uncovers a surprising mechanism: an enzyme called EZH2 drives abnormal cell…
-
New Strategy Targets EZH2 to Block TNBC Metastasis and Restore Chromosomal Stability
Breakthrough in Triple-Negative Breast Cancer: Targeting EZH2 to Halt Metastasis Triple-negative breast cancer (TNBC) remains one of the most aggressive and hard-to-treat forms of breast cancer. A new preclinical study from Weill Cornell Medicine proposes a surprising and hopeful strategy: inhibiting an enzyme called EZH2 to prevent cancer cells from disseminating to distant organs by…